Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis

36Citations
Citations of this article
111Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Adalimumab is used to treat moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) when conventional therapies fail. Aim: To update long-term adalimumab safety from CD and UC trials; the previous report was CD only, 3160 patients/3402 patient-years (PYs). Methods: Treatment-emergent adverse events (AEs; first dose to 70 days after last dose/December 31, 2015) in adults in phase 2/3 and 3/3b trials and open-label extensions were coded using Medical Dictionary for Regulatory Activities (MedDRA-v18.1). Rates were assessed as events/100 (E/100 PYs). Results: The database (16 trials; CD, N = 3606; UC, N = 1739) represented 4145 and 3397 PYs of exposure, respectively. For CD, incidences of any AEs with adalimumab were 60.8%-65.1%, depending on dose, and 71.5% with placebo; for UC, the incidences were 53.5%-54.8% and 56.1%, respectively. Rates of any AEs (CD, 605 E/100 PYs; UC, 361 E/100 PYs), serious AEs (CD, 36.1 E/100 PYs; UC, 18.9 E/100 PYs), and malignancies (CD, 1.2 E/100 PYs; UC, 1.0 E/100 PYs) were similar between current and prior analyses. Apparent rate of opportunistic infections was lowered to 0.3 and 0.2 E/100 PYs for CD and UC, respectively, by recent MedDRA changes excluding oral candidiasis and tuberculosis. Standardised incidence ratios for malignancies were similar to the general population (CD, 1.45 [95% CI, 0.90-2.22]; UC, 1.36 [95% CI, 0.84-2.07]). Demyelinating disorders were uncommon (CD, 0.1 E/100 PYs; UC, <0.1 E/100 PYs). Conclusions: Patients with moderately to severely active Crohn’s disease or ulcerative colitis continued to experience acceptable safety with adalimumab, without new safety signals.

Cite

CITATION STYLE

APA

Colombel, J. F., Sandborn, W. J., Reinisch, W., Peyrin-Biroulet, L., Panaccione, R., Rutgeerts, P., … Read, H. (2018). Long-term safety of adalimumab in clinical trials in adult patients with Crohn’s disease or ulcerative colitis. Alimentary Pharmacology and Therapeutics, 47(2), 219–228. https://doi.org/10.1111/apt.14420

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free